Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2011

01-11-2011 | Original Paper

Longitudinal Change in Cognitive Function and Medication Adherence in HIV-Infected Adults

Authors: Brian W. Becker, April D. Thames, Ellen Woo, Steven A. Castellon, Charles H. Hinkin

Published in: AIDS and Behavior | Issue 8/2011

Login to get access

Abstract

Neuropsychological (NP) dysfunction has been linked to poor medication adherence among HIV-infected adults. However, there is a dearth of research examining longitudinal changes in the relationship between NP status and adherence rates. We hypothesized that declines in NP functioning would be associated with a corresponding decline in medication adherence while stable NP functioning would be associated with stable or improving adherence rates. Participants included 215 HIV-infected adults who underwent cognitive testing at study entry and six months later. Compared to the NP stable group, the NP decline group showed a greater drop in adherence rates. Further analysis revealed that, beyond global NP, learning and memory was significantly associated with changes in adherence rates. These findings further support the link between cognitive functioning and medication adherence and illustrates the importance of documenting changes in cognitive abilities for identifying individuals at risk for poor adherence.
Literature
1.
Karon JM, Dondero TJ, Curran JW. The projected incidence of AIDS and estimated prevalence of HIV infection in the United States. J Acquir Immune Defic Syndr. 1988;1(6):542–50.PubMed
2.
Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Adolescent medicine HIV/AIDS research network. Antiretroviral medication adherence among the reach HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13:27–40.PubMedCrossRef
3.
Casado JL, Sabido R, Perez-Elías MJ, et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther. 1999;4(3):157–61.PubMed
4.
Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282–92.PubMedCrossRef
5.
Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175–82.PubMedCrossRef
6.
Bangsberg DR, Hecht FM, Charlesbois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development off drug resistance in an indigent population. AIDS. 2000;14:357–66.PubMedCrossRef
7.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
8.
Murphy EL, Collier AC, Kalish KA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135:17–26.PubMed
9.
Nieuwkerk PT, Gisolf EH, Reijers MHE, Lange JMA, Danner SA, Sprangers MAG. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS. 2001;15:1985–91.PubMedCrossRef
10.
Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185–94.PubMedCrossRef
11.
Perno CF, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr. 2002;31(3):S118–22.PubMed
12.
Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339–47.PubMedCrossRef
13.
Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175–83.PubMedCrossRef
14.
Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Rosenberger P, Fass RJ. Neuropsychological performance in symptomatic and asymptomatic HIV infection. AIDS. 1993;7:519–24.PubMedCrossRef
15.
Heaton RK, Grant I, Butters N, et al. The HNRC 500—neuropsychology of HIV infection at different disease stages. HIV neurobehavioral research center. J Int Neuropsychol Soc. 1995;1(3):231–51.PubMedCrossRef
16.
Hinkin CH, van Gorp WG, Satz P. Neuropsychological aspects of HIV infection. In: Kaplan HI, Saddock BJ, editors. The comprehensive textbook of psychiatry, vol. VI. Oxford: Blackwell; 1995.
17.
Miller EN, Seines OA, McArthur JC, et al. Neuropsychological performance in HIV-1-infected homosexual men: the multicenter aids cohort study (MACS). Neurology. 1990;40:197–203.PubMed
18.
Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007;26:40–9.PubMedCrossRef
19.
Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV + adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944–50.PubMed
20.
Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:19–25.CrossRef
21.
Levine A, Hinkin C, Castellon S, Mason K, Lam M, Perkins A. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9:355–62.PubMedCrossRef
22.
Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead–Reitan battery: demographic corrections, research findings, and clinical applications. Odessa: Psychological Assessment Resources; 1991.
23.
Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-II-R (SCID). I: History, rationale, and description. Arch. Gen Psychiatry. 1992;49(8):624–9.
24.
Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307–19.PubMedCrossRef
25.
Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009;32(5):389–405.PubMedCrossRef
26.
Contardo C, Black AC, Beauvais J, Dieckhaus K, Rosen MI. Relationship of prospective memory to neuropsychological function and antiretroviral adherence. Arch Clin Neuropsychol. 2009;24:547–54.PubMedCrossRef
27.
Woods SP, Iudicello JE, Moran LM, et al. HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology. 2008;22:110–7.PubMedCrossRef
Metadata
Title
Longitudinal Change in Cognitive Function and Medication Adherence in HIV-Infected Adults
Authors
Brian W. Becker
April D. Thames
Ellen Woo
Steven A. Castellon
Charles H. Hinkin
Publication date
01-11-2011
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2011
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9924-z

Other articles of this Issue 8/2011

AIDS and Behavior 8/2011 Go to the issue

Original Paper

Antidepressant Treatment and Adherence to Antiretroviral Medications Among Privately Insured Persons with HIV/AIDS

Original Paper

Gender and Age Differences in Quality of Life and the Impact of Psychopathological Symptoms Among HIV-Infected Patients

Original Paper

Evaluation of an HIV Prevention Intervention for African Americans and Hispanics: Findings from the VOICES/VOCES Community-Based Organization Behavioral Outcomes Project

Original Paper

Results of a Randomized Controlled Trial of a Peer Mentor HIV/STI Prevention Intervention for Women Over an 18 Month Follow-Up

Brief Report

An Intervention to Assist Men Who Have Sex with Men Disclose Their Serostatus to Family Members: Results from a Pilot Study

Original Paper

Depression and Neurocognitive Performance in Portuguese Patients Infected with HIV
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits